Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
35 articles scientifiques publiés — un praticien à la pointe de la recherche
Référence presse grand public
Cité 1 fois dans les médias — pédagogie reconnue
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
2
2 articles ont été cités au moins 2fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
30
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
7
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
1
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 Ouest-France · 17/12/2019
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxPcm1zRlgyaURHRG0wc1paVnhDTzhxRGp1UjFYV1JNUWpQM0xYVUJxM2c3SVRXV0twcTJMeWkyN0FqODJqY2pSWDZDQkNBWU5FbllKS1pCN3I2MW8yNHAtMThRcDRlWFFsUWhhejZYOEIyTGFuRHdNb0JxX1lGVFNwUlhUZXY5d0FTc3lEVjBtT0dBTWctZjYzMlItX3JCeC0tM1A0ZDlpT0hxRUxFVm1WNk55VmRLdlVDUz
Nature reviews. Rheumatology · 2017
Arthritis & rheumatology (Hoboken, N.J.) · 2020
ObjectiveWe undertook this study to examine microRNA (miRNA) expression across rheumatoid arthritis (RA) phenotypes, along with the effects and mechanisms of action of miRNA‐17‐5p (miR‐17).MethodsA miRNA array was performed in synovial tissue biopsied from patients with naive erosive RA (n = 3) and patients with nonerosive RA (n = 3). MicroRNA‐17 lipoplex was delivered intraarticularly in the murine collagen‐induced arthritis model. Clinical, histologic, and structural effects were studied over the course of arthritis. In‐depth studies of the mechanisms of action of miR‐17 were performed in primary RA fibroblast‐like synoviocytes (FLS) isolated from synovial tissue.ResultsFifty‐five miRNAs including miR‐17 were reduced in erosive RA. The miR‐17 transfection into arthritic paws reduced the clinical inflammation score between day 2 and day 7 (2.8 versus 1.9; P = 0.03). Synovial B cell, T cell, macrophage, and polynuclear neutrophil infiltration was significantly reduced. Structural damage was also decreased, as shown by a reduction in the number of osteoclasts detected using tartrate‐resistant acid phosphatase staining (osteoclast surface/bone surface 32% versus 18%; P = 0.005) and erosion score by computed tomography analysis (2.9 versus 1.7; P = 0.023). Proinflammatory cytokines from the interleukin‐6 (IL‐6) family and IL‐1β expression were also significantly reduced, but tumor necrosis factor was not. MicroRNA‐17 directly targeted the 3′‐untranslated regions of STAT3 and JAK1. STAT3 and JAK1 messenger RNA (mRNA) and protein expression were reduced in RA FLS following miR‐17 transfection. STAT3 and JAK1 mRNA and activation of STAT3, as assessed by immunohistochemistry, were also reduced in injected paws (% stained area 93% versus 62%; P = 0.035).ConclusionWe demonstrate an antiinflammatory and antierosive role of miR‐17 in vivo. This effect involves the suppression of the IL‐6 family autocrine‐amplifying loop through the direct targeting of JAK1 and STAT3.
RMD open · 2020
Objectives Anti-drug antibodies (ADA) are responsible for decreased adalimumab efficacy in axial spondyloarthritis (SpA). We aimed to evaluate the ability of methotrexate (MTX) to decrease adalimumab immunisation. Methods A total of 110 patients eligible to receive adalimumab 40 mg subcutaneously (s.c.) every other week were randomised (1:1 ratio) to receive, 2 weeks before adalimumab (W-2) and weekly, MTX 10 mg s.c. (MTX+) or not (MTX−). ADA detection and adalimumab serum concentration were assessed at weeks 4 (W4), 8 (W8), 12 (W12) and 26 (W26) after starting adalimumab (W0). The primary outcome was the proportion of patients with ADA at W26. Four years after the study completion, we retrospectively analysed adalimumab maintenance in relation with MTX co-treatment duration. Results We analysed data for 107 patients (MTX+; n=52; MTX-; n=55). ADA were detected at W26 in 39/107 (36.4%) patients: 13/52 (25%) in the MTX+ group and 26/55 (47.3%) in the MTX− group (p=0.03). Adalimumab concentration was significantly higher in the MTX+ than MTX− group at W4, W8, W12 and W26. The two groups did not differ in adverse events or efficacy. In the follow-up study, MTX co-treatment >W26 versus no MTX or ≤W26 was significantly associated with adalimumab long-term maintenance (p=0.04). Conclusion MTX reduces the immunogenicity and ameliorate the pharmacokinetics of adalimumab in axial SpA. A prolonged co-treatment of MTX>W26 seems to increase adalimumab long-term maintenance.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Joint bone spine · 2025 · Journal Article
Cormier G, Denis A, Leske C, Varin S, et al.
Joint bone spine · 2024 · Journal Article
Fautrel B, Kedra J, Rempenault C, Juge PA, et al.
Drug discovery today · 2024 · Journal Article
Gaigeard N, Cardon A, Le Goff B, Guicheux J, et al.
Joint bone spine · 2024 · Journal Article
Cadiou S, Tuil R, Le Goff B, Hoppé E, et al.
Frontiers in physiology · 2023 · Journal Article
Prati C, Lequerre T, Le Goff B, Cortet B, et al.
Joint bone spine · 2022 · Review
Berthelot JM, Darrieutort-Laffite C, Le Goff B
Joint bone spine · 2022 · Editorial
Le Goff B
Joint bone spine · 2021 · Journal Article
Berthelot JM, Darrieutort-Laffite C, Trang C, Maugars Y, et al.
Frontiers in medicine · 2021 · Journal Article
Maugars Y, Berthelot JM, Le Goff B, Darrieutort-Laffite C
Joint bone spine · 2021 · Journal Article
Mouterde G, Gandjbakhch F, Le Goff B, Gaudin P, et al.
Joint bone spine · 2021 · Journal Article
Morel J, Tournadre A, Sellam J, Bouhnik Y, et al.
Arthritis & rheumatology (Hoboken, N.J.) · 2020 · Journal Article
Najm A, Masson FM, Preuss P, Georges S, et al.
Annals of the rheumatic diseases · 2020 · Letter
Coiffier G, Couderc M, Seror R, Bart G, et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2019 · Journal Article
El Jamal A, Briolay A, Mebarek S, Le Goff B, et al.
Arthritis research & therapy · 2019 · Journal Article
Berthelot JM, Le Goff B, Maugars Y
Joint bone spine · 2019 · Journal Article
Richez C, Morel J, Cornec D, Daïen C, et al.
Joint bone spine · 2019 · Journal Article
Najm A, le Goff B, Venet G, Garraud T, et al.
RMD open · 2018 · Journal Article
Najm A, Orr C, Gallagher L, Biniecka M, et al.
Joint bone spine · 2018 · Journal Article
Goussault C, Albert JD, Coiffier G, Lamer F, et al.
Bone · 2017 · Journal Article
Bougault C, El Jamal A, Briolay A, Mebarek S, et al.
Joint bone spine · 2017 · Journal Article
Gaigneux E, Cormier G, Varin S, Mérot O, et al.
Joint bone spine · 2023 · Review
Berthelot JM, Brulefert K, Arnolfo P, Le Goff B, et al.
Microorganisms · 2021 · Journal Article
Berthelot JM, Bandiaky ON, Le Goff B, Amador G, et al.
Nature reviews. Rheumatology · 2017 · Journal Article
Orr C, Vieira-Sousa E, Boyle DL, Buch MH, et al.
Joint bone spine · 2021 · Journal Article
Sellam J, Morel J, Tournadre A, Bouhnik Y, et al.
RMD open · 2020 · Journal Article
Ducourau E, Rispens T, Samain M, Dernis E, et al.
Journal of medical case reports · 2020 · Case Reports
Maugars Y, Guillot P, Glémarec J, Berthelot JM, et al.
Calcified tissue international · 2018 · Journal Article
Maugars Y, Bart G, Guillot P, Chemel-Mary M, et al.
Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy Association · 2023 · Multicenter Study
Vincent-Genod D, Rippert P, Coton J, Le Goff L, et al.
Mediators of inflammation · 2019 · Journal Article
Le Goff B, Bouvard B, Lequerre T, Lespessailles E, et al.
Arthritis research & therapy · 2020 · Journal Article
Toussirot E, Marotte H, Mulleman D, Cormier G, et al.
RMD open · 2020 · Journal Article
Ducourau E, Rispens T, Samain M, Dernis E, et al.
BMJ open · 2019 · Clinical Trial Protocol
Cormier G, Le Goff B, Denis A, Varin S, et al.
Joint bone spine · 2018 · Journal Article
Salliot C, Denis A, Dernis E, Andre V, et al.
Microorganisms · 2021 · Journal Article
Berthelot JM, Bandiaky ON, Le Goff B, Amador G, et al.
Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy Association · 2023 · Multicenter Study
Vincent-Genod D, Rippert P, Coton J, Le Goff L, et al.
Arthritis research & therapy · 2018 · Journal Article
Najm A, Le Goff B, Orr C, Thurlings R, et al.
Journal of clinical medicine · 2019 · Journal Article
Darrieutort-Laffite C, Arnolfo P, Garraud T, Adrait A, et al.